Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations

Abstract Since COVID-19 risk of reinfection is of great concern, the safety and efficacy of the mRNA-based vaccines in previously infected populations should be assessed. We studied 78 individuals previously infected with SARS-CoV-19, who received a single dose of BNT162b2 mRNA COVID-19 vaccine, and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shai Efrati, Merav Catalogna, Ramzia Abu Hamad, Amir Hadanny, Adina Bar-Chaim, Patricia Benveniste-Levkovitz, Osnat Levtzion-korach
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b7488fa59c8e41a7a74b90512388b6bf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b7488fa59c8e41a7a74b90512388b6bf
record_format	dspace
spelling	oai:doaj.org-article:b7488fa59c8e41a7a74b90512388b6bf2021-12-02T15:10:39ZSafety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations10.1038/s41598-021-96129-62045-2322https://doaj.org/article/b7488fa59c8e41a7a74b90512388b6bf2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96129-6https://doaj.org/toc/2045-2322Abstract Since COVID-19 risk of reinfection is of great concern, the safety and efficacy of the mRNA-based vaccines in previously infected populations should be assessed. We studied 78 individuals previously infected with SARS-CoV-19, who received a single dose of BNT162b2 mRNA COVID-19 vaccine, and 1:2 ratio matched infection-naïve cohort who received two injections. The evaluation procedure included symptom monitoring, and serological tests. Among the post-infected population, the median IgG-S response after the first vaccine dose was 3.35 AU, compared to 2.38 AU after the second vaccine injection in the infection naive group. A strong correlation was demonstrated between IgG-S level before vaccination, and the corresponding responses after a single vaccine dose (r = 0.8, p < 0.001) in the post infected population. Short-term severe symptoms that required medical attention were found in 6.8% among the post-infected individuals, while none were found in the infection naïve population. Our data suggest that a single vaccine dose is sufficient to induce an intense immune response in post-infected population regardless of seropositivity. Although some short-term safety issues were observed compared to the infection naïve population, a single dose regimen can be considered safe in post-infected populations.Shai EfratiMerav CatalognaRamzia Abu HamadAmir HadannyAdina Bar-ChaimPatricia Benveniste-LevkovitzOsnat Levtzion-korachNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Shai Efrati Merav Catalogna Ramzia Abu Hamad Amir Hadanny Adina Bar-Chaim Patricia Benveniste-Levkovitz Osnat Levtzion-korach Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations
description	Abstract Since COVID-19 risk of reinfection is of great concern, the safety and efficacy of the mRNA-based vaccines in previously infected populations should be assessed. We studied 78 individuals previously infected with SARS-CoV-19, who received a single dose of BNT162b2 mRNA COVID-19 vaccine, and 1:2 ratio matched infection-naïve cohort who received two injections. The evaluation procedure included symptom monitoring, and serological tests. Among the post-infected population, the median IgG-S response after the first vaccine dose was 3.35 AU, compared to 2.38 AU after the second vaccine injection in the infection naive group. A strong correlation was demonstrated between IgG-S level before vaccination, and the corresponding responses after a single vaccine dose (r = 0.8, p < 0.001) in the post infected population. Short-term severe symptoms that required medical attention were found in 6.8% among the post-infected individuals, while none were found in the infection naïve population. Our data suggest that a single vaccine dose is sufficient to induce an intense immune response in post-infected population regardless of seropositivity. Although some short-term safety issues were observed compared to the infection naïve population, a single dose regimen can be considered safe in post-infected populations.
format	article
author	Shai Efrati Merav Catalogna Ramzia Abu Hamad Amir Hadanny Adina Bar-Chaim Patricia Benveniste-Levkovitz Osnat Levtzion-korach
author_facet	Shai Efrati Merav Catalogna Ramzia Abu Hamad Amir Hadanny Adina Bar-Chaim Patricia Benveniste-Levkovitz Osnat Levtzion-korach
author_sort	Shai Efrati
title	Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations
title_short	Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations
title_full	Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations
title_fullStr	Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations
title_full_unstemmed	Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations
title_sort	safety and humoral responses to bnt162b2 mrna vaccination of sars-cov-2 previously infected and naive populations
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/b7488fa59c8e41a7a74b90512388b6bf
work_keys_str_mv	AT shaiefrati safetyandhumoralresponsestobnt162b2mrnavaccinationofsarscov2previouslyinfectedandnaivepopulations AT meravcatalogna safetyandhumoralresponsestobnt162b2mrnavaccinationofsarscov2previouslyinfectedandnaivepopulations AT ramziaabuhamad safetyandhumoralresponsestobnt162b2mrnavaccinationofsarscov2previouslyinfectedandnaivepopulations AT amirhadanny safetyandhumoralresponsestobnt162b2mrnavaccinationofsarscov2previouslyinfectedandnaivepopulations AT adinabarchaim safetyandhumoralresponsestobnt162b2mrnavaccinationofsarscov2previouslyinfectedandnaivepopulations AT patriciabenvenistelevkovitz safetyandhumoralresponsestobnt162b2mrnavaccinationofsarscov2previouslyinfectedandnaivepopulations AT osnatlevtzionkorach safetyandhumoralresponsestobnt162b2mrnavaccinationofsarscov2previouslyinfectedandnaivepopulations
_version_	1718387715948412928

Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations

Ejemplares similares